Authors: J.D. Heidel, J.Y-C. Liu, R.K. Zeidan, Y. Liang, S. Rele, M.E. Davis
Affilation: Calando Pharmaceuticals, United States
Pages: 336 - 337
Keywords: siRNA, deliery, RRM2, nanoparticle, transferrin
Calando Pharmaceuticals is developing siRNA-containing nanoparticle formulations, and its leading formulation that will enter the clinic in 2008 contains the human transferrin protein as a targeting ligand and siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2). Critical parameters in the formulation and function of this therapeutic system will be highlighted using data from pre-clinical investigations. Anti-tumor efficacy is enhanced when the targeted version of the nanoparticles are employed, and results from numerous safety and efficacy studies will be discussed.